Literature DB >> 19761719

IgA nephropathy in the triethnic population of New Mexico.

E G Fischer1, A A Harris, B Carmichael, S L Lathrop, L A Cerilli.   

Abstract

AIMS: IgA nephropathy (IgAN) is the most frequent glomerulonephritis around the globe, but its incidence in the United States is unknown. The disease has a preponderance for certain racial/ethnic groups. Our goals were to retrospectively analyze a series of IgAN biopsies from the state of New Mexico and to calculate an estimated incidence. Then we compared the racial/ethnic composition of our patient cohort to the composition of the New Mexico population and examined the three main racial/ethnic groups for differences in clinical and pathologic parameters.
MATERIALS AND METHODS: Renal biopsies and clinical data from IgAN cases newly diagnosed in New Mexico between 2000 and 2005 were reviewed. We compared the racial/ethnic composition of our patient cohort to the demographic composition of the New Mexico population. Demographic, clinical, and histopathologic variables were analyzed with respect to the patients' race/ethnicity.
RESULTS: The incidence of IgAN in New Mexico was 10.2 cases per million persons per year (9.3 when Henoch-Schönlein purpura cases were excluded). American Indians were twice as frequent in our patient cohort when compared to their demographic representation, with the reverse finding for Non-Hispanic Whites. Hispanics more frequently had nephrotic range proteinuria than Non-Hispanic Whites and American Indians. On renal biopsy, endocapillary proliferative glomerulonephritis was the most common glomerular abnormality, followed by the focal segmental glomerulosclerosis (FSGS)-like pattern. The FSGS-like pattern was more frequent in American Indians and Hispanics than in Non-Hispanic Whites.
CONCLUSIONS: This is the first report of an incidence figure of IgAN for an entire state in the US. American Indian and Hispanic patients had a stronger representation in our cohort than Non-Hispanic Whites, when compared to the general New Mexico population.

Entities:  

Mesh:

Year:  2009        PMID: 19761719

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

1.  Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994-2011.

Authors:  Dita Maixnerova; Eva Jancova; Jelena Skibova; Romana Rysava; Ivan Rychlik; Ondrej Viklicky; Miroslav Merta; Alexander Kolsky; Jana Reiterova; Michaela Neprasova; Jana Kidorova; Eva Honsova; Vladimir Tesar
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

Review 2.  IgA Nephropathy: An Interesting Autoimmune Kidney Disease.

Authors:  Arun Rajasekaran; Bruce A Julian; Dana V Rizk
Journal:  Am J Med Sci       Date:  2020-10-08       Impact factor: 2.378

3.  Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis.

Authors:  Krzysztof Kiryluk; Yifu Li; Simone Sanna-Cherchi; Mersedeh Rohanizadegan; Hitoshi Suzuki; Frank Eitner; Holly J Snyder; Murim Choi; Ping Hou; Francesco Scolari; Claudia Izzi; Maddalena Gigante; Loreto Gesualdo; Silvana Savoldi; Antonio Amoroso; Daniele Cusi; Pasquale Zamboli; Bruce A Julian; Jan Novak; Robert J Wyatt; Krzysztof Mucha; Markus Perola; Kati Kristiansson; Alexander Viktorin; Patrik K Magnusson; Gudmar Thorleifsson; Unnur Thorsteinsdottir; Kari Stefansson; Anne Boland; Marie Metzger; Lise Thibaudin; Christoph Wanner; Kitty J Jager; Shin Goto; Dita Maixnerova; Hussein H Karnib; Judit Nagy; Ulf Panzer; Jingyuan Xie; Nan Chen; Vladimir Tesar; Ichiei Narita; Francois Berthoux; Jürgen Floege; Benedicte Stengel; Hong Zhang; Richard P Lifton; Ali G Gharavi
Journal:  PLoS Genet       Date:  2012-06-21       Impact factor: 5.917

4.  Distribution of nephrologists and regional variation in the clinical severity of IgA nephropathy at biopsy diagnosis in Japan: a cross-sectional study.

Authors:  Yusuke Okabayashi; Nobuo Tsuboi; Hoichi Amano; Yoichi Miyazaki; Tetsuya Kawamura; Makoto Ogura; Ichiei Narita; Toshiharu Ninomiya; Hitoshi Yokoyama; Takashi Yokoo
Journal:  BMJ Open       Date:  2018-10-31       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.